These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14683466)

  • 1. Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders.
    Wood MD
    Curr Drug Targets CNS Neurol Disord; 2003 Dec; 2(6):383-7. PubMed ID: 14683466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse.
    Dalton GL; Lee MD; Kennett GA; Dourish CT; Clifton PG
    Psychopharmacology (Berl); 2006 Mar; 185(1):45-57. PubMed ID: 16470405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury.
    Obata H; Saito S; Sakurazawa S; Sasaki M; Usui T; Goto F
    Pain; 2004 Mar; 108(1-2):163-9. PubMed ID: 15109520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes.
    Dalton GL; Lee MD; Kennett GA; Dourish CT; Clifton PG
    Neuropharmacology; 2004 Apr; 46(5):663-71. PubMed ID: 14996544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT2C receptor involvement in the control of persistence in the reinforced spatial alternation animal model of obsessive-compulsive disorder.
    Papakosta VM; Kalogerakou S; Kontis D; Anyfandi E; Theochari E; Boulougouris V; Papadopoulos S; Panagis G; Tsaltas E
    Behav Brain Res; 2013 Apr; 243():176-83. PubMed ID: 23327741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the 5-HT2C receptor in improving weight-supported stepping in adult rats spinalized as neonates.
    Kao T; Shumsky JS; Jacob-Vadakot S; Himes BT; Murray M; Moxon KA
    Brain Res; 2006 Sep; 1112(1):159-68. PubMed ID: 16914121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM; Rice KC; France CP
    J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration.
    Vicente MA; Zangrossi H
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):389-400. PubMed ID: 21733232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2C receptor modulators: a patent survey.
    Lee J; Jung ME; Lee J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
    Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice.
    Walker EA; Kohut SJ; Hass RW; Brown EK; Prabandham A; Lefever T
    Neuropharmacology; 2005 Dec; 49(8):1210-9. PubMed ID: 16165167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs.
    Isaac M
    Curr Top Med Chem; 2005; 5(1):59-67. PubMed ID: 15638778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short history of the 5-HT
    Palacios JM; Pazos A; Hoyer D
    Psychopharmacology (Berl); 2017 May; 234(9-10):1395-1418. PubMed ID: 28265714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.
    Bagdy G; Graf M; Anheuer ZE; Modos EA; Kantor S
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):399-408. PubMed ID: 11806866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development.
    Wold EA; Wild CT; Cunningham KA; Zhou J
    Curr Top Med Chem; 2019; 19(16):1381-1398. PubMed ID: 31288724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
    Berg KA; Harvey JA; Spampinato U; Clarke WP
    Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
    Adams W; van den Buuse M
    Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation.
    Hackler EA; Turner GH; Gresch PJ; Sengupta S; Deutch AY; Avison MJ; Gore JC; Sanders-Bush E
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1023-9. PubMed ID: 17138863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.